Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need.
Antabio is developing it's antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need.
Antabio was founded in 2009 and is headquartered in Labège, France.
Antabio's innovative PEi program seeks to develop an inhaled product to be used as an adjunct to existing therapy and which will aim to reduce the severity of P. aeruginosa disease and enhance pathogen clearance by targeting the LasB elastase.
Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development.
Antabio has been awarded up to $4.4 million in a second tranche funding from CARB-X, on Jan 02, 2020. The company has raised a total of $42.4M in funding to date.